The therapeutic monoclonal antibody market
By: D. Ecker, et al
Reprinted with the permission of mAbs, 2015 Jan-Feb
Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so that, as of November 10, 2014, there were forty-six monoclonal antibody products on the market in the US and/or Europe for the treatment of a variety of diseases and many of these products have also been approved for commercial sale in other global markets. At the current approval rate of approximately four new products per year, there will be approximately seventy monoclonal antibody products on the market by 2020 with combined world-wide sales of nearly $125 billion.